More IT intelligence can reduce time to therapy for patient support
The delay between when a medication is prescribed and when the patient can receive the prescription is a critical issue in patient care, particularly for specialty pharmaceuticals whose reimbursement can be a challenging hurdle. Many patient-support (hub) service providers, including Lash Group, have addressed one aspect of this with accelerated prior-authorization procedures. Now, Lash is addressing another aspect with AI-powered electronic benefits verification (eBV).
According to the company, a proprietary artificial-intelligence platform, branded as SmartPoint, powers an eBV process that takes advantage of the stored knowledge of “health coverage and payer data collected from millions of manual verifications as a reference base.” With the addition of machine-learning capability as well, the eBV process can predict the outcome of an incoming BV with a measurable degree of certainty, based on the patient’s health plan and other details. If the accuracy of the measurement is high enough, the BV is processed in real time and a benefit summary is sent to the patient’s provider. Lower accuracy, and the BV is routed to a Lash patient counselor for evaluation. The machine-learning capability enables the system to react to new information from counselors and from health plans, so the process can continually improve.
“Benefit verification can be a significant barrier … for the millions of patients whose benefits are still verified manually – through phone calls and paperwork exchanged among provider offices, payers and third-party hub support services providers,” said Tommy Bramley, PhD, president, in a statement. “By applying advanced technologies to the healthcare space and pairing them with expert human intervention when required, we can drive faster speed to therapy and provide a more seamless experience for patients and providers.”
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.